UY37866A - Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. - Google Patents

Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.

Info

Publication number
UY37866A
UY37866A UY0001037866A UY37866A UY37866A UY 37866 A UY37866 A UY 37866A UY 0001037866 A UY0001037866 A UY 0001037866A UY 37866 A UY37866 A UY 37866A UY 37866 A UY37866 A UY 37866A
Authority
UY
Uruguay
Prior art keywords
myc
cbp
cells
inhibit
acetyltranspherase
Prior art date
Application number
UY0001037866A
Other languages
English (en)
Inventor
Raul Medina Jesus
Xinrong Tian
L Graybill Todd
A Heerding Dirk
Hoi Hong Li William
Biju Mangatt
Cuthbert MARTYR
Raphael, (Ralph) Anthony RIVERO
Christina Dimarco
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY37866A publication Critical patent/UY37866A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Nuevos compuestos derivados de bencimidazol, de acuerdo con Fórmula lb, que disminuyen la proteína MYC (c-MYC) en células y / o inhiben la histona acetiltransferasa p300 / CBP y pueden ser útiles en el tratamiento de hipertrofia cardíaca, diabetes, obesidad y enfermedad de hígado graso no alcohólico, VIH, enfermedad renal poliquística, enfermedades inflamatorias, espondilitis anquilosante, psoriasis, artritis psoriásica, artritis reumatoide, enfermedad de Crohn, esclerosis múltiple, cáncer y síndromes precancerosos, y enfermedades asociadas con la desregulación de Myc o la inhibición de la histona acetiltransferasa p300 / CBP.
UY0001037866A 2017-09-07 2018-09-05 Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. UY37866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555164P 2017-09-07 2017-09-07
US201762587004P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
UY37866A true UY37866A (es) 2019-03-29

Family

ID=63686027

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037866A UY37866A (es) 2017-09-07 2018-09-05 Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.

Country Status (3)

Country Link
TW (1) TW201922721A (es)
UY (1) UY37866A (es)
WO (1) WO2019049061A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202045492A (zh) * 2019-02-27 2020-12-16 美商星座製藥公司 P300/cbp hat抑制劑及其使用方法
CN111848626B (zh) * 2019-04-30 2021-11-30 江苏柯菲平医药股份有限公司 Trk激酶抑制剂及其用途
WO2021061823A1 (en) * 2019-09-23 2021-04-01 Boragen, Inc. Chemical compounds
CN110551147B (zh) * 2019-09-29 2021-11-26 蚌埠产品质量监督检验研究院 一种3-环丙基苯硼酸的合成方法
GB201914989D0 (en) * 2019-10-16 2019-11-27 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for TAU Aggregates
CN112190581B (zh) * 2020-11-04 2021-12-24 徐州医科大学 吡咯烷-2-酮类化合物在制备与多发性骨髓瘤有关药物方面的应用
JPWO2022138944A1 (es) * 2020-12-25 2022-06-30
BR112023024371A2 (pt) * 2021-06-02 2024-02-15 Nihon Nohyaku Co Ltd Composto de benzimidazol ou sal do mesmo, agente de controle de filariose canina contendo o mesmo e método de uso do mesmo
CN113387934B (zh) * 2021-06-07 2023-03-07 中山大学 一种多芳基取代咪唑衍生物及其制备方法与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
PL214667B1 (pl) 2000-12-21 2013-08-30 Glaxo Group Ltd Pochodne pirydynoaminy, srodek farmaceutyczny i zastosowanie pochodnych pirymidynoaminy do wytwarzania leku
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
EP2270051B1 (en) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Antibody specific for human PD-1 and CD3
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
DK1761528T3 (da) 2004-06-11 2008-05-05 Japan Tobacco Inc 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidin-derivater og beslægtede forbindelser til behandling af cancer
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
KR101790767B1 (ko) 2009-11-24 2017-10-26 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
BR112014028826A8 (pt) 2012-05-15 2021-07-20 Bristol Myers Squibb Co anticorpos monoclonais, uso de anticorpos anti-pd1, anti-pd-l1 e anti-ctla-4 em imunoterapia e tratamento de câncer, bem como kits e processo de seleção de indivíduo para tratamento com anticorpo anti-pd-1
CA3139031A1 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
US20160235716A1 (en) 2014-09-18 2016-08-18 Abbvie Inc. Spirocyclic hat inhibitors and methods for their use
US10787444B2 (en) * 2015-06-05 2020-09-29 Syros Pharmaceuticals, Inc. Compounds for the modulation of myc activity
CN106977443A (zh) * 2017-04-24 2017-07-25 南昌大学 一类o‑苄基取代的异羟肟酸衍生物及其制备方法和药物的用途

Also Published As

Publication number Publication date
TW201922721A (zh) 2019-06-16
WO2019049061A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
UY37866A (es) Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
EA202191432A1 (ru) Агонисты glp-1r и их применения
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
PH12018501226A1 (en) Methods for treating huntingtons disease
BR112015027319A8 (pt) Métodos e composições para modular a expressão de apolipoproteína (a)
EA201890565A1 (ru) Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз
MX2017013040A (es) Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
BR112018014810A2 (pt) anticorpos anti-fator xi de coagulação
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA200700169A1 (ru) Конденсированные производные пиримидина и их композиции, применимые в качестве модуляторов cxcr3 рецепторов для профилактики и лечения воспалительных и иммунорегуляторных расстройств и заболеваний
CL2008003524A1 (es) Composicion farmaceutica que comprende al menos un inhibidor de proteina quinasa dependiente de arn de doble hebra (pkr), uso de la composicion para el tratamiento de una condicion seleccionada de cancer, anorexia, enfermedad inflamatoria, sepsis, falla cardiaca congestiva, artritis reumatoidea, enfermedad autoinmune, diabetes, fiebre reumatoidea, progenia.
CL2021000328A1 (es) Inhibidores de transglutaminasa 2 (tg2)
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
MX2022007846A (es) Derivados carboxi con propiedades antiinflamatorias.
MX2017008045A (es) Composiciones de polímero parcialmente fluorado curables.
MX2018015410A (es) Esteres de oxaborol y sus usos.
BR112018003291A2 (pt) modulando a expressão da apolipoproteina (a)
EA202190005A1 (ru) Производные 1,3,5-трис(6-метилпиридин-2-илокси)бензола и родственные соединения в качестве лигандов nlrx1 для лечения воспалительных заболеваний
BR112017000462A2 (pt) detergente para lavar louça de pastilha e métodos para a fabricação e uso do mesmo
BR112022017283A2 (pt) Cristalização de 2?-fl
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
PH12017500487A1 (en) Use of heterocyclic fluoroalkenyl sulfone compounds for repelling molluscs
EA202192488A1 (ru) Антитела против tsg-6 и их применения

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204